Background
Methods
Patient background
Histopathological evaluation of TILs
Histopathological evaluation of RCB
RCB-TILs evaluation
Statistical analysis
Results
RCB-TILs and clinicopathological investigation
Parameters | RCB-TILs in all breast cancers (n = 177) | p value | |
---|---|---|---|
Positive (n = 112) | Negative (n = 65) | ||
Age at operation | |||
≤ 56 | 52 (46.4%) | 35 (53.9%) | |
> 56 | 60 (53.6%) | 30 (46.1%) | 0.341 |
Menopause | |||
Pre-menopausal | 44 (39.3%) | 28 (43.1%) | |
Post-menopausal | 68 (60.7%) | 37 (56.9%) | 0.621 |
Tumor size | |||
≤ 2 cm | 19 (17.0%) | 5 (7.7%) | |
> 2 cm | 93 (83.0%) | 60 (92.3%) | 0.082 |
Lymph node status | |||
Negative | 27 (24.1%) | 14 (21.5%) | |
Positive | 85 (75.9%) | 51 (78.5%) | 0.696 |
Nuclear grade | |||
1, 2 | 81 (72.3%) | 56 (86.2%) | |
3 | 31 (27.7%) | 9 (13.8%) | 0.034 |
Ki67 | |||
≤ 14% | 36 (32.1%) | 38 (58.5%) | |
> 14% | 76 (67.9%) | 27 (41.5%) | 0.001 |
Intrinsic subtype | |||
TNBC | 49 (43.8%) | 12 (16.0%) | |
non-TNBC | 63 (56.2%) | 53 (84.0%) | 0.001 |
Intrinsic subtype | |||
HER2BC | 26 (23.2%) | 10 (15.4%) | |
non- HER2BC | 86 (76.8%) | 55 (84.6%) | 0.212 |
Intrinsic subtype | |||
HRBC | 37 (33.0%) | 43 (66.2%) | |
non-HRBC | 75 (67.0%) | 22 (33.8%) | <0.001 |
Pathological response | |||
pCR | 58 (51.8%) | 9 (13.8%) | |
non-pCR | 54 (48.2%) | 56 (86.2%) | <0.001 |
Parameters | TNBC (n = 61) |
p value | HER2BC (n = 36) |
p value | HRBC (n = 80) |
p value | |||
---|---|---|---|---|---|---|---|---|---|
Positive (n = 49) | Negative (n = 12) | Positive (n = 26) | Negative (n = 10) | Positive (n = 37) | Negative (n = 43) | ||||
Age at operation | |||||||||
≤ 56 | 23 (46.9%) | 5 (41.7%) | 12 (46.2%) | 4 (40.0%) | 17 (45.9%) | 26 (60.5%) | |||
> 56 | 26 (53.1%) | 7 (58.3%) | 0.743 | 14 (53.8%) | 6 (60.0%) | 0.519 | 20 (50.1%) | 17 (39.5%) | 0.194 |
Menopause | |||||||||
Pre-menopausal | 17 (34.7%) | 5 (41.7%) | 11 (42.3%) | 3 (30.0%) | 16 (43.2%) | 20 (46.5%) | |||
Post-menopausal | 32 (65.3%) | 7 (58.3%) | 0.652 | 15 (57.7%) | 7 (70.0%) | 0.389 | 21 (56.8%) | 23 (53.5%) | 0.770 |
Tumor size | |||||||||
≤ 2 cm | 7 (14.3%) | 0 (0.0%) | 5 (19.2%) | 1 (10.0%) | 7 (18.9%) | 4 (9.3%) | |||
> 2 cm | 42 (85.7%) | 12 (100.0%) | 0.197 | 21 (80.8%) | 9 (90.0%) | 0.456 | 30 (81.1%) | 39 (90.7%) | 0.179 |
Lymph node status | |||||||||
Negative | 9 (18.4%) | 2 (16.7%) | 8 (30.8%) | 3 (30.0%) | 10 (27.0%) | 9 (20.9%) | |||
Positive | 40 (81.6%) | 10 (83.3%) | 0.630 | 18 (69.2%) | 7 (70.0%) | 0.647 | 27 (73.0%) | 34 (79.1%) | 0.353 |
Nuclear grade | |||||||||
1, 2 | 37 (75.5%) | 7 (58.3%) | 19 (73.1%) | 9 (90.0%) | 25 (67.6%) | 40 (93.0%) | |||
3 | 12 (24.5%) | 5 (41.7%) | 0.234 | 7 (26.9%) | 1 (10.0%) | 0.269 | 12 (32.4%) | 3 (7.0%) | 0.004 |
Ki67 | |||||||||
≤ 14% | 13 (26.5%) | 5 (41.7%) | 10 (38.5%) | 7 (70.0%) | 13 (35.1%) | 26 (60.5%) | |||
> 14% | 36 (73.5%) | 7 (58.3%) | 0.303 | 16 (61.5%) | 3 (30.0%) | 0.090 | 24 (64.9%) | 17 (39.5%) | 0.024 |
Pathological response | |||||||||
pCR | 26 (53.1%) | 2 (16.7%) | 9 (34.6%) | 9 (90.0%) | 15 (40.5%) | 6 (14.0%) | 0.007 | ||
non-pCR | 23 (46.9%) | 10 (83.3%) | 0.023 | 17 (65.4%) | 1 (10.0%) | 0.004 | 22 (59.5%) | 37 (86.0%) |
Analysis of survival according to RCB-TILs
Univariable analysis | Multivariable analysis | ||||||
---|---|---|---|---|---|---|---|
Parameter | Hazard ratio | 95% c.i. |
p value | Hazard ratio | 95% c.i. |
p value | |
All breast cancers (n = 177) | |||||||
Age | ≤56 vs >56 | 0.809 | 0.395–1.657 | 0.561 | |||
Menopause | Pre- vs Post- | 0.840 | 0.408–1.731 | 0.637 | |||
Tumor size (cm) | ≤2 vs >2 | 1.062 | 0.370–3.045 | 0.911 | |||
Lymph node status | Negative vs Positive | 4.157 | 0.990–17.456 | 0.052 | |||
Nuclear grade | 1–2 vs 3 | 1.025 | 0.440–2.389 | 0.954 | |||
Ki67 (%) | ≤14 vs >14 | 0.649 | 0.316–1.331 | 0.238 | |||
Intrinsic subtype | TNBC vs non-TNBC | 1.213 | 0.577–2.550 | 0.611 | |||
Intrinsic subtype | HER2BC vs non- HER2BC | 0.695 | 0.266–1.818 | 0.459 | |||
Intrinsic subtype | HRBC vs non-HRBC | 1.054 | 0.514–2.160 | 0.886 | |||
Pathological response | pCR vs non-pCR | 0.611 | 0.279–1.336 | 0.217 | 1.008 | 0.402–2.524 | 0.987 |
TILs | High vs Low | 0.420 | 0.199–0.885 | 0.022 | 4.785 | 1.169–19.582 | 0.029 |
RCB-TILs | Positive vs Negative | 0.181 | 0.082–0.401 | <0.001 | 0.048 | 0.012–0.188 | <0.001 |
TNBC (n = 61) | |||||||
Age | ≤56 vs >56 | 0.690 | 0.211–2.262 | 0.541 | |||
Menopause | Pre- vs Post- | 0.652 | 0.199–2.136 | 0.480 | |||
Tumor size (cm) | ≤2 vs >2 | 0.550 | 0.119–2.546 | 0.444 | |||
Lymph node status | Negative vs Positive | 0.942 | 0.203–4.359 | 0.939 | |||
Nuclear grade | 1–2 vs 3 | 1.553 | 0.455–5.307 | 0.482 | |||
Ki67 (%) | ≤14 vs >14 | 0.739 | 0.216–2.526 | 0.630 | |||
Pathological response | pCR vs non-pCR | 0.234 | 0.050–1.084 | 0.063 | 0.270 | 0.030–2.466 | 0.246 |
TILs | High vs Low | 0.177 | 0.054–0.583 | 0.004 | 0.243 | 0.071–0.816 | 0.023 |
RCB-TILs | Positive vs Negative | 0.099 | 0.029–0.343 | <0.001 | 0.041 | 0.003–0.573 | 0.018 |
HER2BC (n = 36) | |||||||
Age | ≤56 vs >56 | 1.245 | 0.207–7.493 | 0.811 | |||
Menopause | Pre- vs Post- | 2.507 | 0.280–22.443 | 0.411 | |||
Tumor size (cm) | ≤2 vs >2 | 0.693 | 0.081–6.302 | 0.744 | |||
Lymph node status | Negative vs Positive | 3.732 | 0.072–5.051 | 0.414 | |||
Nuclear grade | 1–2 vs 3 | 0.043 | 0.011–5.216 | 0.513 | |||
Ki67 (%) | ≤14 vs >14 | 0.441 | 0.068–2.623 | 0.364 | |||
Pathological response | pCR vs non-pCR | 0.482 | 0.078–2.847 | 0.415 | 0.702 | 0.108–4.551 | 0.710 |
TILs | High vs Low | 0.123 | 0.020–0.774 | 0.026 | 0.134 | 0.020–0.879 | 0.036 |
RCB-TILs | Positive vs Negative | 0.123 | 0.020–0.774 | 0.026 | 0.134 | 0.020–0.879 | 0.036 |
HRBC (n = 80) | |||||||
Age | ≤56 vs >56 | 0.856 | 0.297–2.467 | 0.773 | |||
Menopause | Pre- vs Post- | 0.769 | 0.270–2.193 | 0.623 | |||
Tumor size (cm) | ≤2 vs >2 | 2.462 | 0.322–18.836 | 0.386 | |||
Lymph node status | Negative vs Positive | 3.682 | 0.151–10.382 | 0.205 | |||
Nuclear grade | 1–2 vs 3 | 1.063 | 0.303–3.811 | 0.930 | |||
Ki67 (%) | ≤14 vs >14 | 0.602 | 0.212–1.738 | 0.344 | |||
Pathological response | pCR vs non-pCR | 1.328 | 0.438–3.973 | 0.614 | 2.123 | 0.667–6.750 | 0.202 |
TILs | High vs Low | 0.992 | 0.311–3.165 | 0.990 | 1.044 | 0.323–3.372 | 0.949 |
RCB-TILs | Positive vs Negative | 0.258 | 0.071–0.932 | 0.039 | 0.081 | 0.016–0.409 | 0.002 |